Literature DB >> 33385361

Rabies control in Liberia: Joint efforts towards zero by 30.

Garmie Voupawoe1, Roland Varkpeh2, Varney Kamara3, Sonpon Sieh4, Abdallah Traoré5, Cristian De Battisti6, Angélique Angot7, Luis Filipe L de J Loureiro8, Baba Soumaré9, Gwenaëlle Dauphin10, Wolde Abebe11, André Coetzer12, Terence Scott13, Louis Nel14, Jesse Blanton15, Laurent Dacheux16, Simon Bonas17, Hervé Bourhy18, Morgane Gourlaouen19, Stefania Leopardi20, Paola De Benedictis21, Monique Léchenne22, Jakob Zinsstag23, Stephanie Mauti24.   

Abstract

Despite declaration as a national priority disease, dog rabies remains endemic in Liberia, with surveillance systems and disease control activities still developing. The objective of these initial efforts was to establish animal rabies diagnostics, foster collaboration between all rabies control stakeholders, and develop a short-term action plan with estimated costs for rabies control and elimination in Liberia. Four rabies diagnostic tests, the direct fluorescent antibody (DFA) test, the direct immunohistochemical test (dRIT), the reverse transcriptase polymerase chain reaction (RT-PCR) assay and the rapid immunochromatographic diagnostic test (RIDT), were implemented at the Central Veterinary Laboratory (CVL) in Monrovia between July 2017 and February 2018. Seven samples (n=7) out of eight suspected animals were confirmed positive for rabies lyssavirus, and molecular analyses revealed that all isolates belonged to the Africa 2 lineage, subgroup H. During a comprehensive in-country One Health rabies stakeholder meeting in 2018, a practical workplan, a short-term action plan and an accurately costed mass dog vaccination strategy were developed. Liberia is currently at stage 1.5/5 of the Stepwise Approach towards Rabies Elimination (SARE) tool, which corresponds with countries that are scaling up local-level interventions (e.g. dog vaccination campaigns) to the national level. Overall an estimated 5.3 - 8 million USD invested over 13 years is needed to eliminate rabies in Liberia by 2030. Liberia still has a long road to become free from dog-rabies. However, the dialogue between all relevant stakeholders took place, and disease surveillance considerably improved through implementing rabies diagnosis at the CVL. The joint efforts of diverse national and international stakeholders laid important foundations to achieve the goal of zero dog-mediated human rabies deaths by 2030.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Diagnostic; GDREP tool; Liberia; Phylogenetics; Rabies; SARE tool

Mesh:

Substances:

Year:  2020        PMID: 33385361     DOI: 10.1016/j.actatropica.2020.105787

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  4 in total

1.  A generalizable one health framework for the control of zoonotic diseases.

Authors:  Ria R Ghai; Ryan M Wallace; James C Kile; Trevor R Shoemaker; Antonio R Vieira; Maria E Negron; Sean V Shadomy; Julie R Sinclair; Grace W Goryoka; Stephanie J Salyer; Casey Barton Behravesh
Journal:  Sci Rep       Date:  2022-05-21       Impact factor: 4.996

Review 2.  Rabies in the Tropics.

Authors:  Charles E Rupprecht; Reeta S Mani; Philip P Mshelbwala; Sergio E Recuenco; Michael P Ward
Journal:  Curr Trop Med Rep       Date:  2022-03-28

3.  Complete Genome Sequences of Five Rabies Virus Strains Obtained from Domestic Carnivores in Liberia.

Authors:  Stephanie Mauti; Garmie Voupawoe; Simon Bonas; Varney Kamara; Hervé Bourhy; Morgane Gourlaouen; Paola De Benedictis; Jakob Zinsstag; Laurent Dacheux
Journal:  Microbiol Resour Announc       Date:  2022-01-20

4.  Capacity Building Efforts for Rabies Diagnosis in Resource-Limited Countries in Sub-Saharan Africa: A Case Report of the Central Veterinary Laboratory in Benin (Parakou).

Authors:  Fidelia Djegui; Morgane Gourlaouen; Andre Coetzer; Rachidatou Adjin; Rogatien Tohozin; Stefania Leopardi; Stephanie Mauti; Yao Akpo; Corneille Gnanvi; Louis H Nel; Paola De Benedictis
Journal:  Front Vet Sci       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.